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Abstract: Glycosylation is a metabolic pathway consisting of the enzymatic modification 
of proteins and lipids through the stepwise addition of sugars that gives rise to glycoconjugates. 
To determine the full complement of glycoconjugates that cells produce (the glycome),  
a variety of genes are involved, many of which are regulated by DNA methylation.  
The aim of the present review is to briefly describe some relevant examples of 
glycosylation-related genes whose DNA methylation has been implicated in their 
regulation and to focus on the intriguing case of a glycosyltransferase gene (B3GALT5). 
Aberrant promoter methylation is frequently at the basis of their modulation in cancer,  
but in the case of B3GALT5, at least two promoters are involved in regulation, and  
a complex interplay is reported to occur between transcription factors, chromatin remodelling 
and DNA methylation of typical CpG islands or even of other CpG dinucleotides. 
Transcription of the B3GALT5 gene underwent a particular evolutionary fate, so that 
promoter hypermethylation, acting on one transcript, and hypomethylation of other 
sequences, acting on the other, cooperate on one gene to obtain full cancer-associated 
silencing. The findings may also help in unravelling the complex origin of serum CA19.9 
antigen circulating in some patients. 
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1. Introduction 
The extreme complexity of multicellular organisms requires that their molecular and cellular 
interactions are tuned with absolute precision in terms of temporal and spatial organization. Compared with 
that of a simple multicellular organism of few hundred cells only, such as C. elegans, the organization 
of a mammal of several billion cells is more complex by many orders of magnitude. This level of 
complexity requires that the information contained in the genetic code is translated in molecular and 
cellular interactions by mechanisms ensuring both fidelity and flexibility. While fidelity is easily 
guaranteed by the classical deterministic mechanisms at the basis of the template-driven biosynthesis 
of nucleic acids and proteins, flexibility requires highly-tunable and promptly-reversible mechanisms. 
Evolution has developed levels of control of gene expression and of protein function that fulfill these 
requirements: the first is represented by the epigenetic mechanisms regulating transcription; the second 
by posttranslational modifications of proteins, among which glycosylation plays a pivotal role. 
Glycosylation is a metabolic pathway consisting of the enzymatic modification of proteins and 
lipids through the stepwise addition of sugars that gives rise to the glycoconjugates (or glycans): 
glycoproteins, glycolipids and proteoglycans. Unlike the biosynthesis of nucleic acids or proteins, 
which is a deterministic process, glycosylation is a stochastic (or probabilistic) event in which the final 
sugar chain product results from the cooperative and competitive interaction of multiple players.  
A pivotal role in glycosylation is played by glycosyltransferases, the enzymes responsible for the  
step-wise addition of individual sugar residues, but other factors, such as the availability of the sugar 
donors, of the protein or lipid substrates, or the action of the glycohydrolases, contribute to determine 
the full complement of glycans that cells produce (the glycome). Historically, protein- or lipid-linked 
sugar chains have been considered to play multiple biological roles [1], and in general, it can be said 
that they mediate the ―fine tuning‖ of cellular and molecular interactions. This means that, besides 
contributing to biological processes through carbohydrate-protein interactions, sugar chains can also 
regulate protein-protein interactions. An example of a carbohydrate-protein interaction is provided by 
the cell adhesion phenomena mediated through members of the selectin family and their carbohydrate 
ligands as the sialyl Lewis antigens [2]. An example of protein-protein interaction finely tuned by the 
action of carbohydrates is provided by immunoglobulins G, where the sugar chain N-linked to 
asparagine 297 of their Fc portion determines the pro- or anti-inflammatory effects of the antibody [3]. 
Epigenetic chromatin modifications and protein or lipid glycosylation, although profoundly 
different from the mechanistic point of view, share important key features. First of all, they are both 
the product of non-deterministic processes. DNA methylation and histone methylation/acetylation 
depend on the relative abundance of the enzymes adding or removing methyl and acetyl groups,  
and glycosylation depends on that of enzymes adding or removing sugar residues. Second, both 
processes are reversible, although usually very stable. Third, although both modifications can have  
a huge functional impact on DNA and proteins, the basic information carried by these macromolecules 
resides at the level of their primary sequence. 
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Epigenetic mechanisms deeply impact the glycosylation machinery through either DNA 
methylation or histone methylation/acetylation, or both (many of them are reviewed in [4] and [5]). 
Relevant examples include the biosynthesis of bioactive molecules, such as the histo-blood group 
ABO, Lewis and Sda antigens, the T antigen, the mucins [6] and the GlcNAcylation of proteins, 
which, in turn, affects the epigenome per se [7,8]. 
Through epigenetic mechanisms of regulation, the genome can cope with environmental challenges 
without the need to select advantageous random mutations, a process that would require many 
generations. Analogously, an antibody with a given antigen specificity can change its downstream 
effects simply by adding or removing a specific monosaccharide on its N-linked chain. 
It has been proposed that the epigenetic control of networks of genes, like those involved in 
glycosylation, is a crucial resource used by higher organisms to compete or collaborate with 
microorganisms [5] in response to environmental stimuli. Even more interesting, there is increasing 
evidence of the transgenerational transmission of epigenetic changes [9,10]; however, the molecular 
mechanisms responsible for the transmission of these changes to gametes remain unknown. 
Despite such an enormous possibility of future research, the present state-of-the-art concerning the 
complex interplay among genetic and epigenetic mechanisms regulating the expression of 
glycosylation-related genes (glycogenes) is far from being elucidated. 
In the last few decades, an innumerable amount of research articles reported the silencing of genes 
determined by DNA methylation in the context of CpG islands located near promoters and the 
consequent possibility of reactivating them through action on demethylating agents, with particular 
focus on cancer-associated gene silencing. This overwhelming stream of data point to the equation: 
DNA hypermethylation equals cancer equals gene silencing. However, it has been reported since the 
1980s [11,12] that cancer transformation is indeed associated with a global DNA hypomethylation,  
since the majority of CpG dinucleotides, scattered in the genome at a relative low density and far from 
gene promoters, are indeed hypomethylated in cancer [13,14]. In other words, only CG dinucleotides 
within DNA regions of high CpG density, i.e., CpG islands frequently located near gene promoters, are 
hypermethylated in cancer and hypomethylated in normal cells, while the opposite occurs for all other 
CpGs. While the strong association between CpG island hypermethylation and gene silencing in 
cancer has been widely documented and characterized for a long time, the role of the hypermethylation 
of the other CpG dinucleotides in normal cells versus hypomethylation in cancer has not been 
investigated until very recently. An increasing amount of recent data suggests that the methylation of 
CpG dinucleotides outside typical CpG islands plays a relevant role in alternative promoter usage, 
regulation of short and non-coding RNAs, alternative RNA processing and enhancer activity, even in 
the context of neoplastic transformation [15]. 
The aim of the present review is to briefly describe some relevant examples of glycogenes 
controlled through DNA methylation and to focus on the intriguing case of a glycosyltransferase gene, 
the regulation of which involves at least two promoters and a complex interplay between transcription 
factors, chromatin remodelling, DNA methylation of typical CpG islands or even of other CpG 
dinucleotides. It appears responsible for efficient cancer-associated silencing and probably fine  
tissue-specific expression of a galactosyltransferase enzyme isoform (B3GALT5), which also 
underwent a particular evolutionary fate. 
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2. Methylation Control of Glycogenes 
The global effect of methylation on the glycome was studied by high-throughput techniques in cells 
treated with 5-aza-2’-deoxycytidine (5AZA), a DNA methyltransferase inhibitor that has shown 
substantial potency in reactivating epigenetically silenced tumor suppressor genes. It has revealed  
a strong impact on sialylation, core fucosylation and N-linked branching [16]. Other relevant examples 
are the following. 
Glycosyltransferases: A variety of glycosyltransferases are regulated by epigenetic mechanisms, 
mainly promoter methylation. Aberrant promoter methylation is often at the basis of glycosyltransferase 
modulation in cancer. Examples are provided by enzymes directly involved in selectin ligand 
biosynthesis [17], such as sialyltransferase ST3GAL6 [18] and fucosyltransferase FUT3 [19], as well 
as enzymes affecting indirectly selectin ligand biosynthesis, because of their involvement in the 
biosynthesis of alternative structures, such as ST6GALNAC6 [20], the sulfate transporter,  
DTDST [21], or B4GALNT2 [22–24]. The latter provides an example of a gene downregulated in 
cancer, in which promoter demethylation is a condition necessary, but not sufficient to restore a 
physiological level of enzyme expression [25]. Furthermore, glycosyltransferases involved in the high 
branching of the N-linked chains of glycoproteins, such as GlcNAcT-IV [26,27] and GlcNAcT-V [28], 
display methylation-dependent modulation in cancer. Finally, the downregulation of the 
glycosyltransferase responsible for the biosynthesis of A antigen (of the ABO blood group system), 
frequently observed in cancer, is at least partially dependent on the hypermethylation of  
its promoter [29–31]. 
Enzymes of sugar nucleotides biosynthesis: The methylation-dependent inhibition of UDP-GlcNAc 
2-epimerase/ManNAc kinase, the key enzyme of the biosynthesis of the sugar donor, CMP-sialic acid, 
may be responsible for decreased sialylation, even in the presence of unaltered sialyltransferase  
levels [32,33]. This modification can be induced by latent HIV infection of T-cells [32]. 
Galectins: Galectins are galactose-specific mammalian lectins that mediate a variety of biological 
phenomena, including cell proliferation and apoptosis, either through binding to galactose-containing 
glycoconjugates or through carbohydrate-independent intracellular mechanisms [34]. Promoter methylation 
appears to be the major mechanism regulating galectin expression in physiological and pathological 
conditions. Galectin-1, a product of the LGALS1 locus, induces apoptosis of T-lymphocytes and cancer 
cells. In colorectal cancer, galectin-1 expression is silenced by promoter hypermethylation, resulting in 
reduced apoptosis [35], while in mixed lineage leukemia (MLL)-rearranged B-lymphoblastic leukemias, 
galectin-1 is overexpressed, because of the histone methylation of the LGALS1 promoter [36]. 
Galectin-3 expression is frequently altered in cancers with divergent effects on tumor growth [37]. In 
prostate tissues, the galectin-3 promoter is unmethylated, while it becomes strongly methylated in the 
early stages of prostate cancer, but less methylated in high-grade cancers [38,39]. Galectin-3 
modulation is controlled by promoter methylation also in thyroid cancer [40], in colon cancer of the 
mucinous type [41] and in pituitary tumors [42]. Galectin-7 acts as a tumor suppressor in gastric cancer, 
and its downregulation is due to promoter hypermethylation [43], while in lymphoma progression, it is 
upregulated, because of promoter hypo-methylation [44]. 
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3. The Intriguing Case of the B3GALT5 Gene 
β1,3 galactosyltransferase B3GALT5 is responsible for type 1 chain oligosaccharide synthesis, 
including the selectin ligand, sialyl-Lewis a, epitope of tumor marker CA19.9 and other Lewis 
antigens, such as Lewis a and Lewis b (Figure 1) [45,46]. 
Figure 1. Biosynthesis of type 1 chain Lewis antigens. B3GALTs include B3GALT5, 
B3GALT1 and B3GALT2; ST3GALs are α2,3 sialyltransferases acting on galactose and 
include ST3GAL3 and possibly ST3GAL4; FUT3 is a unique α1,4 fucosyltransferase acting 
on N-acetylglucosamine; FUT1 and FUT2 are α1,2 fucosyltransferases acting on galactose. 
 
In mammary gland, thymus and trachea, as well as in some human cancer cell lines, transcription is 
mainly driven by a promoter that was found to be sensitive to nuclear factor NF-Y also in mice [47]. 
Due to the conservation among distant mammalian species, it was referred to as the native promoter. In 
the organs of the gastrointestinal tract (such as the colon, stomach and pancreas) acts another promoter, 
stronger than the native promoter [47–49]. This alternative promoter has a retroviral origin (named LTR), 
which was probably acquired about 25–30 million years ago [50] and is regulated through the hepatocyte 
nuclear factor HNF1 [48,49]. In various cell lines of different tissue origin, but even among those 
derived from the same tissue, B3GALT5 transcript, as a whole, is differentially expressed [45,51]. 
Moreover, it is strongly downregulated in colon cancer with respect to the normal mucosa [48,52]. 
Surprisingly, the amounts of transcription factors involved in the regulation of either transcript were 
not correlated with the expression levels of the cognate transcript. In particular, NF-Y is rather 
ubiquitous [53] and well detected in several cell lines, where the native B3GALT5 transcript is 
completely absent, or in colon cancer biopsies, where it is faintly detected [54]. Similarly, HNF1α or β, 
or both, are also easily detected in cell lines or tissues, including colon cancers, where the levels of the 
B3GALT5 LTR transcript are minimal or undetectable, opening the question about the mechanisms 
responsible for tissue-specific expression and cancer downregulation of both transcripts [55]. 
Interestingly, the native promoter is located between two CpG islands, while the 650 bp-long LTR 
transposon, which includes a shorter LTR first exon and the cognate promoter, contains only seven 
dispersed CG pairs, and no CpG island is present in the proximal sequences (Figure 2). 
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Figure 2. Genomic organization and DNA methylation of the B3GALT5 gene. In the upper 
part, the genomic sequence of chromosome 21 (0.26 Mbp) encompassing B3GALT5 and 
intergenic regions is presented. The scale starts at 40.87 Mbp and ends at 41.13 Mbp of 
NCBI Reference Sequence: NC_000021.8. The LTR transposon starts at bp 41029095 of 
such a sequence. Between alternative 5'UTRs, exons 1A and 1 (LTR) are the most relevant 
in various tissues. In the lower part, about 50 Kbp were enlarged to show transcription 
factor binding sites, CpG islands (CGI, in red), CpG short islands (CGsI) of at least 100 bp 
(pink), CG dinucleotides present in the LTR transposon and the two main transcripts. 
 
4. Regulation of B3GALT5 Native Promoter 
Methylation analysis of CpG islands 1 and 2 surrounding the native promoter, performed by both 
quantitative pyrosequencing and direct bisulfite sequencing of 12 and 66 CG dinucleotides of CpG 
islands 1 and 2, respectively, indicated a strong inverse correlation between transcript expression and 
DNA methylation status [54]. In particular, in HuCC-T1 cells, which express the highest level of the 
transcript, CpG 2 appeared almost unmethylated, and CpG island 1 was just scarcely methylated (mean 
methylation levels ~20%). In MKN-45 and MCF-7 cell lines, where the expression levels of transcript 
are from low to moderate, CpG island 1 was more methylated (mean methylation values ~80% in both 
lines) while CpG island 2 was almost unmethylated in MCF-7 and mildly methylated in MKN-45 
(mean methylation levels ~30%). In HCT-15 and MDA-MB-231 cells, where the transcript is 
undetectable, both CpG islands were hypermethylated (form 70% to 90%). In matched normal and 
tumor colon samples, the methylation levels of both islands were increased in cancer with respect to 
the corresponding normal mucosa. In the latter, where the expression of the transcript is detectable at 
different levels, mean methylation values of CpG island 1 were below 50%, and those of CpG island 2 
below 20%. In cancer samples, this increases up to 60%–70% in CpG island 1 and up to 40% in CpG 
island 2. Similarly, the degree of methylation was higher in breast cancer biopsies than in normal 
counterparts, suggesting that DNA methylation of the B3GALT5 native promoter probably accounts for 
transcript silencing in cancer. 
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The quantitative ChIP assay from the above-mentioned cell lines expressing different levels of 
B3GALT5 native transcript confirmed that the transcriptional activity of the native promoter is 
associated with chromatin status. In fact, high expression of the transcript (HuCC-T1 cells) was found 
together with high levels of modifications associated with transcriptionally competent chromatin 
(H3K4me3, H3K79me2, H3K9Ac and H3K9-14Ac) and low levels of those related to silenced 
chromatin (H3K27me2 and H4K20me3). Moderate to low expression of the transcript (MCF-7 and  
MKN-45 cells) was associated with a similar pattern, with quantitative differences especially in  
MKN-45 cells. The absence of the transcript (HCT-15 and MDA-MB-231 cells) was related to the 
opposite histone code. These cell lines, in fact, resulted in being negative for H3K4me3, H3K79me2 
and H3K9-14Ac and positive for H3K27me2, H4K20me3 and H3K9Ac. 
Treatment of such cells for different times with different concentrations of DNA methyltransferase 
inhibitor 5AZA or histone deacetylase inhibitor Trichostatin A (TSA), or with a combination of both, 
was unable to restore a detectable expression. However, the treatment was able to reduce methylation 
from ~80% to ~60% in MDA-MB-231 and from ~70% to ~40% in HCT-15. Indeed, both agents were 
able to increase the expression of the transcript in MKN-45 cells that express a low amount per se of 
the transcript. In particular, either TSA or 5AZA treatments increased the expression by ~80%. A 
combination of both drugs failed to provide any further improvement. In line with expression finding, 
pyrosequencing analysis of MKN-45 cells treated with 5AZA showed demethylation of both islands. 
Altogether, the results suggest that complex epigenetic modulation underlies the regulation of the 
native B3GALT5 promoter (Table 1). 
Table 1. Epigenetic features affecting B3GALT5 transcripts in various cell lines.  
 HuCC-T1 COLO-205 HCT-15 MKN-45 MCF-7 MDA-MB-231 
NATIVE TRANSCRIPT       
Expression levels ++ ++ - + + - 
Effect of 5AZA = ND = ↑ ND = 
Effect of TSA = ND = ↑ ND = 
Methylation status of CpG island 1/2 (%) 20/5 ND 80/75 80/30 80/5 90/80 
H3K27me2, H4K20me3 very low ND high low low high 
H3K4me3, H3K79me2, H3K9Ac, H3K9-14Ac very high ND low high high low 
LTR TRANSCRIPT       
Expression levels - ++++ - ++ - - 
Effect of 5AZA = ↓↓ = ↓↓ ND ND 
Effect of TSA = = = = ND ND 
ND: not determined. TSA, Trichostatin A. 
5. Regulation of the B3GALT5 LTR Promoter 
In MKN-45 cells, the LTR promoter of B3GALT5 is also expressed, and the amount under  
steady-state conditions is about eight-times higher than that of the native transcript. Surprisingly, the 
sensitivity to the same drugs was totally different: TSA treatment had no effect on the LTR transcript, 
while 5AZA strongly impaired expression. Treatment with 5AZA of COLO-205 cells, which express the 
LTR transcript at the highest levels found, provided similar results: strong silencing of the B3GALT5 
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LTR transcript and no effect on HNF1. Interestingly, LTR promoter analysis in vitro indicated that the 
HNF1 binding site is the only functional part of the LTR promoter, and that no other binding sites, for 
stimulatory or inhibitory factors, are physiologically relevant [55]. Conversely, DNA demethylation 
obtained through 5AZA treatment reproduced in vitro the downregulation of the transcript observed 
among cell lines and cancer biopsies in vivo. In fact, in treated cells, the levels of the B3GALT5 LTR 
transcript decreased from 3–10 to less than 0.2 fg/pg β-actin, while the amounts of HNF1 remained 
unchanged, as found in colon cancer biopsies. Since LTR and proximal sequences do not contain CpG 
islands, the methylation-sensitive DNA sequences probably represent element(s) involved in 
transcriptional regulation residing outside the LTR sequence and distant from the promoter. Alignment 
of the LTR sequence and the whole B3GALT5 gene in the context of chromosome 21 (Figure 2) 
revealed that the CpG islands regulating transcription of the native B3GALT5 mRNA are the only 
typical promoter-associated CpG islands present. However, shorter stretches of CpG dinucleotides, 
referred to as CpG short islands, were detected using the EMBOSS Cpgplot software, as reported [55].  
They were found one in an intron, and the others in the intergenic regions [55]. Unfortunately, due to 
the extremely high homology of this human sequence with that of the other primates sharing the LTR 
transposon [50], no prediction can be made in silico about the relevance of any such islands. 
The methylation of stretches of CpG dinucleotides shorter than CpG islands associated with 
promoters is emerging as a relevant aspect of transcriptional control [15], being responsible for the 
recruitment of alternative promoters, regulation of non-coding RNA synthesis or modulation of 
enhancer activity. In particular, hypomethylation of enhancer sequences is reported to negatively 
regulate transcription in cancer and during tissue differentiation [15]. The occurrence of distal 
regulatory elements binding transcription factors in a methylation-dependent manner was recently 
reported even in breast cancer [56]. B3GALT5 transcription thus represents a promising model to 
address such novel issues, since hypomethylation of distant sequences, acting on the LTR transcript, 
and promoter hypermethylation, acting on the native transcript [54,55], cooperate on one gene to 
obtain full cancer-associated silencing. 
Since the two transcripts differ in their 5'UTRs only, the involvement of a common non-coding 
RNA in the regulation of both can be hypothesized. However, since the effect of demethylating agents 
on the two transcripts is almost the opposite, the existence of a regulatory 3' CpG island sequence 
appears not probable. On the other hand, the involvement of transcriptional activators requiring the 
methylation of specific CG dinucleotides for efficient binding can be postulated. In this regard, we have 
started performing bisulfite sequencing of stretches of CG dinucleotides located at various distances 
from the LTR promoter. Preliminary results in cancer cell lines suggest an association between the 
methylation of specific CG dinucleotides and the expression levels of the LTR transcript, thus 
supporting such a working hypothesis. 
The fine methylation-dependent silencing of B3GALT5 reported in colon cancer has the potential to 
represent a wider cancer-associated phenomenon, suggesting that many cancers, including those arising 
in the pancreas or stomach, may lack the expression of B3GALT5 transcripts and cognate Lewis 
antigens. In light of very recent findings demonstrating that the CA19.9 detected by immunohistochemistry 
in cancer specimens seems to be a technical artifact [57], the problem of the origin of CA19.9 
circulating in cancer patient sera appears very relevant due to the clinical implications. In fact, the 
assessment of the actual CA19.9 status of a colon cancer may be very important for the prognosis, 
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since the expression of the true antigen promotes angiogenesis and, in turn, tumor growth [57]. On the 
other side, recent findings indicate that the value of serum CA19.9 is not able to predict the actual 
expression of the antigen by colon cancer cells, as it has been assumed so far [58]. Our working 
hypothesis involves the possibility that mainly normal epithelial cells of gastrointestinal origin express 
B3GALT5 and cognate type 1 chain Lewis antigens, due to the strong epigenetic constrains. Metabolic 
pathways of such cells may be deranged as a consequence of the invading tumor mass, resulting in an 
increased reabsorption of the CA19.9 antigen in the blood stream. Interestingly, in cells of different 
histological origin as those of the prostate, it was recently reported that a defined CA19.9 molecule, 
where the sLea antigen is carried by MUC1 mucin, a different β1,3 galactosyltransferase isoenzyme, 
B3GALT1, is specifically involved in the biosynthesis, which appears upregulated by the enhancement 
of acetylated histone-3 and histone-4 induced by suberoylanilide hydroxamic acid [59]. 
6. Conclusions 
The role of DNA methylation has been restricted for several years to CpGs belonging to islands 
located nearby gene promoters, with particular emphasis on their hypermethylated status associated 
with gene silencing in cancer and on the possibility to restore expression using demethylating agents. 
The B3GALT5 gene offers an intriguing example of the role of distant DNA sequences in controlling  
a promoter of retroviral origin, where CpG dinucleotides are probably dispersed or assembled in  
non-canonical islands. In this case, demethylation determines gene silencing and is associated with 
cancer. Concurrently, another promoter of the same gene is instead affected by the methylation status 
of classic CpG islands, but its activity is poorly restored by demethylating agents. Noteworthy is that 
the transcript levels correlate with enzyme activity and, in turn, substrate glycosylation in the case of 
B3GALT5 (51), while this is not yet known for some other epigenetically-regulated glycogenes.  
Future studies are necessary to directly show the link between epigenetic regulation of transcription 
and the actual effect on the cell glycosylation pattern. 
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